Managing Editor, Senior Health Care News Editor
Jonathan Block is the Managing Editor and Senior Health Care News Editor at Seeking Alpha. With a Master's in Public Health from CUNY Graduate School of Public Health, he brings expertise in the healthcare sector to his writing. His articles cover a wide range of topics, including stock analysis, market trends, and industry news.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
Jonathan Block's coverage focuses on investment analysis, press releases, and data citations related to sales & marketing and automotive industries. He would likely be interested in pitches that provide in-depth analysis of stock performance, company news, and market trends within these sectors.
Given his focus on investment analysis and citation of data, Jonathan may find value in pitches from financial experts who can offer unique insights into the potential impact of various factors on stock performance or industry trends.
While Jonathan does not have a specific geographic focus mentioned but given the nature of his articles focusing mainly on companies listed in US stock exchanges (NASDAQ: HAS; NYSE: MTN), it is safe to assume he has an interest primarily in the US market.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Clinical research organization ICON Plc ( NASDAQ: ICLR ) has adjusted its 2024 outlook ranges for both revenue and adjusted EPS.
Shares of Viking Therapeutics ( NASDAQ: VKTX ) are down ~4% in after-hours trading Wednesday, even though the company's Q1 2024 financial results beat on the bottom line
By: Jonathan Block
Regeneron Pharmaceuticals and Mammoth Biosciences join forces to develop CRISPR-based gene editing therapies for various tissues and cell types. Read more here.
J.P. Morgan upgrades Doximity to neutral, citing little downside risk amid its current valuation. Read more here.
By: Jonathan Block
The U.S. FDA has granted Fast Track designation to Compass Therapeutics' ( NASDAQ: CMPX ) CTX-009 in combination with paclitaxel for previously treated advanced biliary tract cancer.
By: Jonathan Block
Teladoc Health ( NYSE: TDOC ) shares are down ~3% in after-hours trading Thursday after the telehealth provider's Q1 2024 results missed on the bottom line . Revenue was a beat.
By: Jonathan Block
NASDAQ: GILD Recommended For You More Trending News Recommended For You More Trending News About GILD Stock
By: Jonathan Block
Despite releasing Q1 2024 results that beat on both lines, Dexcom ( NASDAQ: DXCM ) is down ~7% in after-hours trading Thursday.
AbbVie beats Q1 expectations with strong financial results as well as a boosted 2024 outlook, but shares down 3%. Read more here.
By: Jonathan Block
A federal judge in Massachusetts has set a date for oral arguments in a case led by Verano Holdings that challenges federal marijuana prohibition laws. Read more here.
(833) 317-6278 
